| |
NEWS RELEASES
|
|
|
|
|
|
|
|
Editor’s note: Watch a video of
Dr. Jeffrey Towbin discuss findings from the study. To receive a
copy of the entire video, or arrange an interview with Dr. Towbin,
please contact Carol
Wittman.
|
HOUSTON (Aug. 17, 2006)
– A genetic discovery sheds new light on the cause of cardiomyopathy
and sudden death in young adults, which originates in the previously
overlooked right ventricle of the heart, said the chief of
pediatric cardiology at
Texas Children’s Hospital and a researcher at Baylor
College of Medicine (BCM) in Houston.
In a report that
appears online today in the journal
Circulation Research, Dr.
Jeffrey Towbin, professor of pediatrics at BCM and chief of
pediatric cardiology at TCH, reports that a study in mice identifies
conclusively for the first time genetic origins of cardiomyopathy,
one of the leading causes of sudden cardiac death in young adults.
“We are getting to the underlying cause of this disease,” said
Towbin, principal investigator of the study. “For the first time, we
have taken a human disease gene and put it into an animal model so
that we can study its mechanisms in greater detail.”
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a rare,
progressive condition that causes diseased heart muscle and impairs
cardiac function. In many cases, ARVC leads to fatigue, irregular
heartbeat (arrhythmia), and, potentially, heart failure and sudden
cardiac death.
In a previous study, Towbin and colleagues first identified
mutations in the desmoplakin gene, which encodes a protein in the
connecting junction between heart cells. In this study, funded by
the National
Institutes of Health and the National
Heart, Lung, and Blood Institute, the authors implanted a mutant
human desmoplakin gene into mice, which resulted in the mice’s
cardiac integrity being compromised, leading to dilation of the
right ventricle, buildup of scar and fatty tissue, and arrhythmia.
Towbin calls ARVC “underrecognized” in the United States primarily
because of its relative newness and difficulty evaluating the right
ventricle technically, which can lead to misdiagnosis and improper
treatment. Statistics of its prevalence in the United States have
yet to be determined, but in Italy the disease is known to be the
leading cause of sudden cardiac death in otherwise healthy young
adults.
“ARVC is underrecognized here in the United States because of the
novelty of the disorder and the lack of advances in technology that
assess the right ventricle,” said Towbin. “But I predict that in the
next several years this will be shown to be a key player in sudden
cardiac death.”
The new findings will help pediatric and adult cardiology experts
better understand the root cause of ARVC and advance the care of
patients with this specific abnormality, Towbin said.
“We now have the genetic ability – that is, making a diagnosis off
of a blood test of the gene – to evaluate these patients from the
perspective of the disease’s origin,” said Towbin. “Hopefully we
will be able to engineer new targeted therapies on the basis of
these findings.”
Towbin’s coauthors include first author Dr. Zhao Yang, of BCM, as
well as contributors from Johns Hopkins University, University of
Arizona, Harvard Medical School, and the University of Padua in
Italy.
|
|